Syed Ahmad, MD

Articles

Synopsis of Angiogenesis Inhibitors in Oncology

Lee M. Ellis, MD, FACS;Wenbiao Liu, MD;Fan Fan, MD;Young Do Jung, MD, PhD;Niels Reinmuth, MD;Oliver Stoeltzing, MD;Akihiko Takeda, MD;Morihisa Akagi, MD;Alexander A. Parikh, MD;Syed Ahmad, MD

May 1st 2002

Angiogenesis is a dynamic process essential for primary tumor growth and metastases. New insights into the basic understanding of the biologic processes responsible for angiogenesis have led to the characterization of potential therapeutic targets. Several strategies for the development of antiangiogenic therapeutic modalities have been employed, including agents that (1) decrease the activity of specific angiogenic factors, (2) decrease the activity of endothelial survival factors, (3) increase the activity of naturally occurring antiangiogenic agents, or (4) indirectly downregulate angiogenic and survival factor activity.

Angiopoietins and Their Role in Colon Cancer Angiogenesis

Lee M. Ellis, MD, FACS;Syed Ahmad, MD;Wenbiao Liu, MD

April 1st 2002

Tumor angiogenesis is a complicated process that is regulated by numerous factors simultaneously and in a coordinated fashion.

Role of Angiogenesis Inhibitors in Cancer Treatment

Lee M. Ellis, MD, FACS;Wenbiao Liu, MD;Niels Reinmuth, MD;Raymond M. Shaheen, MD;Young Do Jung, MD, PhD;Syed Ahmad, MD

July 1st 2001

Angiogenesis is essential for the growth of both primary andmetastatic tumors. This process, more complex than was previously thought,